Korea Pharmaceutical Bio Association Holds 1st AI New Drug Development Advisory Committee in 2025
May 14, 2025
|
At the meeting held at the Parnas Hotel in Gangnam-gu, Seoul on the 13th, a ceremony was also held for the appointment of Kang Jae-woo, CEO of Eisen Science, who joined as a new member, and Nam Ho-jung, a professor at the Gwangju Institute of Science and Technology.
Roh Yeon-hong, president of the Korea Pharmaceutical and Biological Association, said, `AI technology is no longer an option, but a task directly related to industrial survival.' `We ask for continuous cooperation and professional advice from advisors to help the pharmaceutical and biological industry leap into a high-tech strategic industry through the development of new AI drugs.'
At this meeting, ▲ AI New Drug Development Education Project Advancement Plan ▲ AI New Drug Development Convergence Task Plan ▲ AI New Drug Development Infrastructure Construction and Support Plan were consulted and discussed. The advisors agreed to expand the target of the current educational program from the incumbent to the task solving applicable to practice. In particular, "Exposing the interest in solving problems in the field of new drug development in the curriculum through team teaching linked to university professors and industry experts will also help supply and demand high-quality human resources."
In addition, various advice was given, such as automating the creation of a common technical document (CTD) using AI to improve work efficiency, expanding programs linked to national tasks, and promoting AI new drug development societies.
The association plans to strengthen online and offline practical education centered on LAIDD (Lectures on AI-driven Drug Discovery), an AI new drug development education platform, and establish a systematic education system to cultivate convergent talents who can be immediately put into the field. In addition, it is also seeking ways to advance AI new drug development education projects from a long-term perspective.
Meanwhile, the association has been operating LAIDD since 2021 as part of the Ministry of Health and Welfare and the Korea Health Industry Promotion Agency's 'AI-utilized new drug development education and promotion project'. As of April this year, the number of subscribers exceeded 10,000, and offline practical training based on this is also continuously expanding. In particular, the Mentoring Project', in which five professional mentors select trainees and carry out long-term team projects for three months, marks its third anniversary this year, and has produced a total of 87 field-type talents so far. In addition, 'AI New Drug Development Boot Camp', which began last year, received high attention, with the first 50 students closing in one minute at the time of the first recruitment, and accordingly, the second additional training was conducted. The association plans to recruit trainees for the two education programs from May to June.
This article was translated by Naver AI translator.
